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Abstract
Author Manuscript

Objective: To advance understanding the effectiveness of evidence-based treatments for
comorbid posttraumatic stress and substance use disorders (PTSD and SUD), research must
provide a more nuanced picture of how substance use affects change in PTSD symptoms over the
course of treatments, and whether prolonged exposure techniques can be efficacious during active
substance use. A dataset that included patients with PTSD/subthreshold PTSD and SUD treated
with an exposure-based intervention provided an opportunity to conduct a secondary analysis to
test how patients’ substance use impacted PTSD change over treatment.
Method: We applied growth models to week-to-week PTSD symptom and substance use changes
during treatment and follow-up of a randomized controlled trial of two cognitive behavioral
treatments for PTSD and SUD: Concurrent Treatment of PTSD and SUD Using Prolonged
Exposure (COPE) and Relapse Prevention Therapy (RPT). Cross-lagged analyses were used to
determine whether prior week substance use impacted subsequent PTSD symptom severity.

Author Manuscript

Results: Both treatments evidenced significant reductions in PTSD symptom severity. In the
context of continued substance use, results suggest that individuals still benefit from exposurebased treatment.
Conclusion: Results provide evidence that RPT and COPE both led to significant reductions in
PTSD, providing further support that exposure-based techniques tailored for SUD can be
conducted without jeopardizing PTSD or SUD outcomes. Implications for clinical decisionmaking around treatment selection are discussed.

Corresponding author: Denise A. Hien (denise.hien@smithers.rutgers.edu).
This manuscript was jointly first authored by Hien and Zumberg
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Two decades of literature clearly document the wide scope of problems associated with
comorbid posttraumatic stress disorder (PTSD) in the lives of people seeking treatment for
substance use disorders (SUD). These problems include poorer treatment prognosis, longer
hospital stays for treatment, lower treatment compliance, higher suicide rates, and less
support for achieving and maintaining sobriety than patients with SUD without PTSD
(Greenfield et al., 2007; McCauley, Killeen, Gros, Brady, & Back, 2012). Despite the fact
that the health care burden of such patients is high, many questions about the optimal
treatment practices across the co-occurring PTSD and SUD (PTSD and SUD) population
remain unanswered.

Author Manuscript

Knowledge to date on PTSD and SUD treatment is primarily based on randomized
controlled trials (RCT; e.g., Back, Foa, Killeen, Mills, et al., 2014; Hien et al., 2009; Hien,
Cohen, Miele, Litt, & Capstick, 2004; Mills et al., 2012), systematic reviews (e.g., Simpson,
Lehavot, & Petrakis, 2017; Debora van Dam, Vedel, Ehring, & Emmelkamp, 2012), and
several meta-analyses (e.g., Roberts, Roberts, Jones, & Bisson, 2015; van Dam, Vedel,
Ehring, & Emmelkamp, 2012). Taken as a whole, findings suggest that trauma processing
models such as prolonged exposure may be superior to coping based, present-focused
approaches in reducing both PTSD and substance use symptoms (e.g., Roberts, Roberts,
Jones, & Bisson, 2015). However, few studies to date have examined how trauma symptoms
change over the course of treatment while participants are actively using substances and
under what levels of substance use a trauma processing approach like prolonged exposure
can be safely used (e.g., Hien et al., 2015; McCauley et al., 2012; Simpson et al., 2017).
Researchers have argued that through examining how individuals symptoms change during
psychotherapy, we will be better able to elucidate mechanisms of action and inform clinical
decision-making (Kahn & Schneider, 2013; Kazdin, 2009; Laurenceau, Hayes, & Feldman,
2007).

Author Manuscript

To better explicate the relationship between PTSD symptoms and substance use during
treatment, one line of research has employed cross-lagged or time-lagged models which can
examine the impact of changes in one symptom domain across time and problem area. In an
RCT for concurrent PTSD and SUD treatment, Hien et al. (2010) found that SUD
improvement reliably followed PTSD improvement, but found no converse association
between SUD change and subsequent PTSD improvement. Recently, Kaczkurkin, Asnaani,
Alpert, and Foa, (2016) extended growth models to examine the lagged effects of PTSD
symptoms on alcohol craving within a trial of integrated treatment combinations for PTSD
and SUD (naltrexone vs. placebo, with or without prolonged exposure). When PTSD
symptoms (at time t) were compared to subsequent alcohol craving (at time t + 1),
improvement in PTSD symptom severity was associated with diminished alcohol craving;
however, no interactions between PTSD symptoms and the four treatment combinations
were observed. Although growth models have begun to provide important information on
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course of symptom change, it is largely unknown how active substance use during treatment
impacts the delivery of an exposure-based therapy simultaneously targeting PTSD and
substance dependence symptoms, such as Concurrent Treatment of PTSD and SUD using
Prolonged Exposure (COPE; Back, Foa, Killeen, Teesson, et al., 2014)).

Author Manuscript
Author Manuscript

One recently completed RCT (Ruglass et al., 2017) affords the opportunity to explore these
questions. Ruglass et al. (2017) compared two cognitive behavioral treatments for PTSD and
SUD: COPE, an integrated, trauma- and addiction-focused treatment with modified
prolonged exposure, and Relapse Prevention Therapy (RPT; Carroll, 1998), a SUD-focused
treatment. The trial provided evidence of the efficacy of both treatments for reducing PTSD
and SUD symptom severity relative to an active monitoring control group (AMCG). COPE
and RPT significantly decreased PTSD symptoms and days of substance use relative to
AMCG at the end of treatment as well as at the 3 month follow-up. Although the difference
between COPE and RPT was not significant in the complete sample, the subset of
participants with full (versus subthreshold) PTSD demonstrated significantly greater
reduction of PTSD severity in COPE relative to RPT. When compared to COPE, RPT
showed significantly more improvement in SUD outcome at end-of-treatment. At 3-month
follow-up, COPE and RPT maintained their treatment gains and were not significantly
different in PTSD severity or days of primary substance use. It remains unclear, however,
whether concurrent substance use interacts with PTSD symptom levels to moderate
treatment outcomes. In addition to its research implications for understanding the dynamics
of PTSD and SUD, this is a clinically salient issue. Therapists conducting exposure therapy
with substance abusing patients have voiced concern that continued substance use during
PE-based interventions may worsen PTSD symptoms, interfere with the treatment process,
and increase risk of relapse (van Minnen, Harned, Zoellner, & Mills, 2012; Van Minnen,
Wessel, Dijkstra, & Roelofs, 2002).

Purpose of the Present Study

Author Manuscript

The present study, therefore, examined how PTSD symptom severity changed among
individuals with PTSD and SUD over time (i.e., during the treatment and posttreatment
phases), and how those changes were influenced by ongoing substance use during treatment.
To that end, we conducted a secondary analysis of the RCT of COPE and RPT (Ruglass et
al., 2017) by estimating a series of piecewise mixed-effects models. Study aims were twofold. First, we aimed to examine (a) how PTSD symptom severity changed over the course
of the active treatment phase and posttreatment phase by treatment type (ie., COPE, RPT)
and (b) whether there were differences in PTSD symptom severity based on ongoing
substance use during treatment. Second, by looking at the joint influences of treatment type
and ongoing substance use during treatment, we sought to explore whether there was any
indication that applying an exposure-based treatment would be more or less beneficial than
standard CBT for SUD for addressing PTSD symptom severity for those who continue to
use substances. We anticipated that higher weekly substance use would be associated with
higher PTSD symptom severity in the subsequent week of treatment regardless of type of
treatment.
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Method
Participants
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Participants were recruited through advertisements and outpatient referrals in New York City
between September 2008 and January 2014 and provided written informed consent prior to
baseline assessment. To be eligible participants met Diagnostic and Statistical Manual of
Mental Disorders, fourth edition, text revision (DSM-IV-TR) (American Psychiatric
Association (APA), 2000)) criteria for full PTSD or subthreshold PTSD (Grubaugh et al.,
2005). We employed the most common definition of subthreshold PTSD which requires an
individual to meet Criteria A (exposure to a traumatic stressor), B (re-experiencing
symptoms), either C (symptoms of avoidance and/or numbing) or D (increased arousal
symptoms), E (symptom duration of at least 1 month), and F (significant distress or
impairment of functioning) (Blanchard, Hickling, Taylor, Loos, & Gerardi, 1994). Our
decision to include subthreshold PTSD was informed by prior research: using the Blanchard
et al. (2004) criteria, various large scale studies have shown that subthreshold PTSD is
associated with levels of impairment, distress, and comorbidity comparable to full PTSD and
should be considered a clinically relevant diagnostic group. In addition to full or
subthreshold PTSD, participants were required to meet DSM-IV-TR criteria for either past
or current alcohol or substance dependence and alcohol/substance use in the prior 3 months.
Given the chronic, relapsing nature of SUDs in the context of co-occurring mental health
disorders (Bradizza, Stasiewicz, & Paas, 2006; Jin, Rourke, Patterson, Taylor, & Grant,
1998), we included individuals with past dependence who were currently using substances.
Exclusion criteria were: 1. Psychotic, schizoaffective or bipolar disorder; 2. Current severe
depression or suicide risk; 3. Participation in PTSD-specific treatment; 4. Start or regimen
change of any psychotropic medications 8 weeks before study participation; 5. Organic
mental syndrome. The institutional review board of the City College of New York approved
all procedures.

Author Manuscript

The CONSORT diagram in Figure 1 provides information on study design, participant flow
and attrition and Supplementary Table 1 includes information about attendance at each
session. The majority of patients received at least 5 sessions (COPE 22/39,56%; RPT 30/43,
70%), while roughly half of those in COPE (17/39, 43.6%) and RPT (22/43, 51.2%)
received an adequate dose of treatment, which was defined as attending 8 or more sessions
(Najavits, 2015). Moreover, the pattern of findings across treatment groups did not differ
statistically by treatment attendance as referenced in the primary outcome paper (Ruglass et
al., 2017; see Supplementary Table 1), nor were there differences in who received an
adequate dose. All participants met criteria for either current alcohol or substance
dependence except for two individuals in the RPT group who met criteria for past alcohol
dependence. Further descriptions of all study procedures including randomization, the
interventions and fidelity, and data collection are described in Ruglass et al. (2017).
Randomization
Randomization was stratified by sex, baseline severity of substance and alcohol dependence
(high or low operationalized from median split of Addiction Severity Index Lite composite
scores) and PTSD severity (high or low defined by the cutoff score of 60 on the Clinician-

J Consult Clin Psychol. Author manuscript; available in PMC 2019 October 01.

Hien et al.

Page 5

Author Manuscript

Administered PTSD Scale). Urn randomization procedures were employed to balance these
factors across groups. An independent biostatistician conducted the randomization
allocation. A research coordinator revealed group allocation to participants after they
provided informed consent. All research assessors were blind to group allocation.
Interventions

Author Manuscript

Two manualized psychotherapy treatments, COPE and RPT, consisted of 12 individual
weekly sessions lasting 90 minutes. COPE integrates the empirically supported models of
PE for PTSD (Back, Foa, Killeen, Teesson, et al., 2014; Foa, Molnar, & Cashman, 1995;
Foa, Chrestman, & Gilboa-Schechtman, 2009) and RPT for SUD (Carroll, 1996; Marlatt &
Donovan, 2005). Psychoeducation about the functional relationship between PTSD and SUD
is provided during the first three sessions. To address behavioral avoidance and fear
associated with traumatic memories, in-vivo and imaginal exposures begin in session four
and five, respectively, and continue through session eleven. Imaginal narratives are audiorecorded for daily listening between sessions. Relapse prevention strategies are reviewed
during each 90-minute session. Between sessions, participants recorded progress of exposure
exercises, substance use cravings, and use of coping skills.
RPT (Carroll, 1996; Marlatt & Donovan, 2005) is a cognitive-behavioral intervention for
SUDs that focuses on the acquisition of coping strategies to manage situations that increase
risk of substance use relapse. Coping strategies are acquired through psychoeducation, roleplays and active problem-solving exercises combined with at-home assignments all geared
towards increasing participants’ self-efficacy in preventing relapse1.
Measures

Author Manuscript
Author Manuscript

PTSD.—PTSD diagnosis was assessed at baseline with the Clinician-Administered PTSD
Scale (CAPS; Blake et al., 1995). PTSD symptom severity was measured at each weekly
intervention visit and all pre- and post-treatment assessments, using the modified PTSD
Symptom Scale Self-Report (MPSS-SR; Falsetti, Resnick, Resick, & Kilpatrick, 1993)
which assessed the past 7 days of self-reported PTSD symptom severity. The MPSS-SR
yielded a total score comprised of the sum of frequency and intensity ratings of each of the
17 DSM-IV-TR PTSD symptoms. Scores range from 0 to 119. A recent psychometric study
of the MPSS-SR with similar comorbid PTSD and SUD treatment samples demonstrated its
high concurrent validity with the CAPS, and suggest it is a reliable and valid tool for
monitoring PTSD symptom severity (Lesia M. Ruglass, Papini, Trub, & Hien, 2014). In
addition, Ruglass and colleagues (2014) found that the rationally-derived three-category
severity classification for the CAPS correctly classified 69% of women with PTSD and SUD
at posttreatment. We used this three-category classification to examine whether individuals
were in one of three categories at posttreatment: asymptomatic (0 – 17points), mild/
subthreshold (17.5-34.99), and threshold (35+).

1Participants randomized to AMCG received weekly assessments during the in-treatment period but not followed during the posttreatment period. They were not included in the present study as the aims were to compare the two cognitive behavioral therapies over
the in-treatment and post-treatment phases.
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Substance Use.—Primary SUD diagnosis was assessed using the Structured Clinical
Interview for DSM-IV for Axis I Disorders (SCID-I; First, Spitzer, Gibbon, & Williams,
2002). The primary SUD diagnosis was determined by selecting the SUD diagnosis (if there
was more than one) that had the greatest number of dependence criteria from the SCID
and/or the highest level of use in the past month. Weekly Days of Substance Use (DSU) was
measured using the Substance Use Inventory (SUI; Weiss, Hufford, & Najavits, 1995), a
self-report measure of past 7 day substance use. Participants completed the SUI weekly
during treatment and at all pre- and post-treatment assessments. Scores represent the number
of days of use of the primary substance and range from 0 to 7.
DSM-IV Diagnoses.—The SCID-I was used to assess the presence of current or past
anxiety, mood, or psychotic disorders. These diagnoses were assessed for the purposes of
determining exclusion criteria in the study.

Author Manuscript

Demographics.—Age, sex, race/ethnicity, education, employment pattern, and income
were collected during the baseline interview. See Ruglass et al. (2017) for more a more
detailed description of all study measures.
Data Analysis

Author Manuscript
Author Manuscript

Piecewise two-level mixed-effect models were estimated using Stata Statistical Software:
Release 14.2 (StataCorp, 2015). All randomized participants were included in analyses and
thus models represent the intent-to-treat sample. To examine the first aim, a piecewise linear
growth model was specified using the following equation: Yijd =( b0ia + b1ia (week – 15)ija +
εija) + ( b0ib + b1ib (week – 15)ijb + εijb) (UCLA Statistical Consulting Group, n.d.) and the
mixed command with the nocons option. The constant was suppressed in the model because
the model includes two intercepts (i.e., two constants). In this model, Yij represents
individual i’s PTSD symptom severity at time j for indicator d. The subscript d, denotes
whether the value of Yij is based on one of two indicator variables, either subscript a or b.
Time was represented by week 15, so that the intercept in the piecewise model (i.e., when X
= 0) would represent individual i’s PTSD symptom severity at either posttreatment
(subscript b, information to the right of bolded plus sign) or the time infinitely close to
posttreatment, but not yet posttreatment (subscript a, information to the left of the bolded
plus sign). Therefore, the intercept with a subscript can be understood as the intercept at the
end of the treatment phase, while the intercept with the subscript b can be understood as the
intercept at the beginning of the posttreatment phase. A significance test was computed to
examine whether the value of the two intercepts was significantly different, indicating the
necessity of a piecewise model. The piecewise model also yields two slopes: the slope to the
left of the bolded plus sign (subscript a) is the linear rate of change for the treatment period,
while the slope to the right of the bolded plus sign (subscript b) is the linear rate of change
for the posttreatment period. The main effect and moderating role of treatment (i.e., COPE
vs RPT) was then examined by including treatment as a predictor in the model, as well as
the interaction between treatment and time during the treatment and posttreatment phases.
To examine the impact of continued substance use, we determined the weekly DSU using
the frequency variable of the SUI for each individual’s primary substance. Weekly DSU was

J Consult Clin Psychol. Author manuscript; available in PMC 2019 October 01.

Hien et al.

Page 7

Author Manuscript

lagged by one time point and was then included in the model as a predictor, along with all
two - way interactions between lagged DSU and all significant functions of time (e.g., timetreatment phase, time-posttreatment phase).
To examine the second aim, we estimated a final model that included both treatment and
lagged DSU, as well as all two- and three-way interactions between treatment, lagged DSU,
and significant functions of time (e.g., time-treatment phase, time-posttreatment phase). To
present the most parsimonious model, final models only included interactions when p < .10
and/or interactions that were important for interpretation. Model fit was examined using
Akaike’s Information criterion (AIC) and Schwarz’s Bayesian information criterion (BIC).

Author Manuscript

Testing of power in these complex mixed-effects models is exceedingly difficult, and clear
conventions are lacking. The unstandardized coefficient estimates convey the difference
between treatments, and thus are directly related to the power of hypothesis tests
(Raudenbush & Liu, 2000). In line with this view, Dorey (2011) argued that after a study is
conducted, confidence intervals are more informative than a post-hoc power analysis: "Once
a study has been completed and analyzed, the confidence interval reveals how much, or
little, has been learned and the power will not contribute any meaningful additional
information (p.620)." Biesanz, Deeb-Sossa, Papadakis, Bollen, and Curran (2004) echo
these points and note that confidence intervals can be used to see how power varies across
estimates and time in mixed-effects models. As such, we include confidence intervals around
all reported estimates along with effect sizes (i.e., Cohen’s (Cohen, 1988) d), where
appropriate, using the equation of Feingold (equation 1; 2009), dividing the product of the
unstandardized coefficient and assessment length by the pooled within-group standard
deviation of PTSD. Effect size confidence intervals were derived from the growth model
effect size using the equations of Feingold (2015).

Author Manuscript

Results
All demographic information for the participants randomized to COPE (n = 39) and RPT (n
= 43) are presented in Table 1, along with descriptive information on the outcomes variables
at baseline and post-treatment. There were no significant differences between the two groups
on demographic variables, nor were there differences on PTSD symptom severity or weekly
DSU at baseline, post-treatment, or three-month follow-up.
Aim one: How did PTSD symptom severity change during the active treatment phase and
posttreatment?
Parameter estimates and fit statistics for all models are presented in Table 2.

Author Manuscript

The shape of change: Piecewise linear growth model.—A piecewise linear growth
model was fit to the data with a breakpoint set at posttreatment and a random intercept and
results indicated that a piecewise model was a good fit to the data. Specifically, results
indicated that the intercept at the end of the treatment phase was (B = 22.24; 95% CI [16.51,
27.97], p < .001), while the intercept at the beginning of the posttreatment phase was (B =
29.98; 95% CI [24.10, 27.97], p < .001). The 7.74 point difference between these two
intercepts was found to be significant (p = .002) indicating a discontinuous change between
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the treatment and posttreatment phase. Results also continued a significant difference in the
rate of change between the two phases (p < .001). During the treatment phase, there was a
significant linear decline in PTSD symptom severity (B = −2.28; 95% CI [−2.61,−1.95], p
< .001, d = −1.31), but there was no significant change during the posttreatment phase (B =
−0.27; 95% CI [−0.81,0.26], p = .321, d = −0.03).

Author Manuscript

Influence of treatment type: Model including treatment type and its interaction
with time during the treatment phase.—Treatment type was added to the model as a
predictor, as well the interaction between treatment and time during the treatment phase.
Given that there was no growth to model during posttreatment phase, we did not include
interactions between treatment and time during the posttreatment phase. Results indicated
that there was a significant interaction between treatment type and the linear function of time
(B = −0.52; 95% CI [−0.95,−0.10], p = .016, d = .−0.30). Inspection of the simple slopes
indicated that COPE was associated with a more rapid decline in PTSD symptom severity (B
= −2.57; 95% CI [−2.96,−2.17], p < .001, d = −1.47), compared to RPT (B = −2.04; 95% CI
[−2.42 ,−1.66], p < .001, d =−1.17). Despite COPE being associated with more rapid decline
of PTSD symptom severity, the clinical meaningfulness of this difference is small as it
represents less than a point difference of change during each week of treatment. Further,
there was no evidence of a main effect of treatment type on PTSD symptom severity at
posttreatment (B = −6.24; 95% CI [−16.36, 3.88], p = .227, d = −0.26), suggesting that any
difference in the rate of change was not associated with a significant difference in PTSD
symptom severity by the end of treatment.

Author Manuscript

Influence of continued substance use: Model including lagged DSU and its
interaction with time during the treatment phase.—Lagged DSU was added to the
model as a predictor, as well as the interaction between lagged DSU and time during the
treatment phase. Results indicated that lagged DSU did not interact with time during the
treatment phase in the prediction of PTSD symptom severity scores (B = 0.10; 95% CI
[−0.02,0.22], p = .112, d = .05).There was a main effect of lagged DSU at posttreatment (B
= 1.50; 95% CI [0.21,2.80], p = .023, d = .84), indicating that a one-unit change in lagged
DSU (e.g., going from 0 to 1 days of use) was associated with 1.50 points higher on PTSD
symptom severity.
Aim two: Was one treatment more beneficial for those who continue to use substances?

Author Manuscript

Joint influences of treatment and continued substance use: Model including
lagged DSU, treatment, and all two- and three-way interactions.—The final
model was estimated with the inclusion of both treatment type and lagged DSU, as well as
all two- and three-way interactions between lagged DSU, treatment type, and time during
the treatment phase. To present the most parsimonious model, only interaction terms wherep
<.10 were included. The final model indicated that there were no significant three-way
interactions between treatment type, lagged DSU, and time during the treatment phase. In
addition, the two-way interaction between treatment type and lagged DSU was nonsignificant. However, there were two significant two-way interactions. Specifically, there
was a significant interaction between treatment type and time during the treatment phase (B
= −0.80; 95% CI [−1.35,−0.24], p = .005, d = −0.44) and a significant interaction with
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lagged DSU and time during the treatment phase (B = 0.14; 95% CI [0.02,0.26], p = .026, d
= .08).

Author Manuscript
Author Manuscript

In order to examine the joint impact of the significant two-way interactions between
treatment type and time and lagged DSU and time, we examined the simple slopes to
determine the mean PTSD symptom severity at posttreatment for those in RPT and COPE at
zero, one, four, and seven days of use per week of the primary substance (see Figure 2).
Given that this was a piecewise model, we had two possible intercepts to plot. We chose to
plot the intercept that represented that time infinitely close to posttreatment, but not
posttreatment because (1) the standard errors were smaller at this point allowing for more
power to detect an effect and (2) results indicated that there was not significant change in
PTSD symptom severity during the posttreatment phase. The bottom shaded region suggests
asymptomatic levels of PTSD symptom severity (about 17 points and lower), while the
shaded region above it suggests mild/subthreshold PTSD symptom severity on the MPSSSR (about 17.5-34.99 points) (Ruglass et al., 2014). Examination of the figure suggests that
at the end of the treatment phase, the only group that had mean levels of PTSD symptom
severity in the asymptomatic range, were those in COPE that were abstinent from their
primary substance in the week prior to the end of the treatment phase. The only group that
had mean levels of PTSD symptom severity in the threshold range, were individuals in RPT
who used their primary substance of abuse daily in the week prior to the end of treatment.
For individuals in all other groups, mean levels of PTSD symptom severity were in the mild/
subthreshold range. However, error bars are overlapping in each of these groups, except for
those in COPE with no days of use and those in RPT with daily use in the week prior to the
end of the treatment phase. Therefore, results suggest that those in RPT with daily use fared
significantly worse than those in COPE who were abstinent, but all other groups achieved
similar levels of PTSD symptom severity by the end of the treatment phase, regardless of
treatment or levels of substance use.

Discussion

Author Manuscript

The present study examined pathways of change in PTSD symptom severity as well as the
impact of ongoing substance use levels on PTSD severity by comparing an exposure-based
trauma-processing, integrated PTSD and SUD treatment approach (COPE) to a cognitive
behavioral intervention for SUD alone (RPT). Given the need for a nuanced analysis of
psychotherapy process in this relatively understudied clinical population, we investigated the
following: 1) how patients’ PTSD symptom severity changed over time and whether there
were differences based on (a) treatment type or (b) ongoing use of the primary substance of
abuse during treatment; and 2) whether there was any evidence that either COPE or RPT
were more favorable for PTSD outcomes for individuals who continue to use substances.
Impact of Treatment on PTSD Symptom Severity
Over the course of both treatments, PTSD symptoms significantly decreased throughout the
trial with each treatment showing a large effect of time. In contrast, the present study took
into consideration in-treatment PTSD changes, as well as the rate of such change, and found
that patients who received COPE had a significantly faster rate of PTSD change over
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treatment than did those who received RPT; however, this difference was not judged to be
clinically meaningful (i.e., only about a 2 point difference each week, interaction between
treatment and time was a small effect) and was not associated with a main effect of treatment
type at posttreatment. The findings do provide additional support for the use of exposurebased approaches with individuals with PTSD who also have SUD. Our results demonstrate
that in contrast to commonly held beliefs that addressing trauma directly using prolonged
exposure techniques might cause a patient to relapse or become more symptomatic (e.g., van
Minnen, Harned, Zoellner & Mills, 2012), patients can tolerate and quickly benefit from
these skills and techniques. Patients receiving RPT, with its unitary focus on building refusal
skills and self-efficacy, also derived benefits in their PTSD symptoms, albeit at a slightly
slower pace. By posttreatment, patients in both groups had significantly reduced PTSD
severity, regardless of the differences in rate of change observed during treatment.

Author Manuscript

Impact of Continued Substance Use on PTSD Symptom Severity

Author Manuscript

Previous studies with PTSD and SUD samples (e.g., Hien et al., 2010; Kaczkurkin et al.,
2016; Ouimette, Read, Wade, & Tirone, 2010) have provided support for within treatment
changes in PTSD symptoms influencing substance use in the proximal session. Similarly,
changes in PTSD during treatment overall have been shown to impact longer-term substance
use outcomes over time (Hien et al., 2010). In contrast, the present study addressed a gap in
the existing research on the topic of symptom domain influences through testing the impact
of previous week’s substance use upon the current week’s PTSD symptoms (e.g.,
association between substance use in session 1 on PTSD symptom severity on session 2,
etc.). Our analysis focused on answering an important clinical question for therapists
considering the delivery of prolonged exposure-based interventions to active substance
users. How does the level of substance use during treatment impact PTSD reductions?
Coffey, Schumacher, Brady, and Cotton (2007) identified that those who were able to be
abstinent at baseline demonstrated significant reductions in PTSD during the first two weeks
of treatment. Evidence from the present study revealed that levels of substance use at the end
of treatment (i.e., session 12) were associated with weekly PTSD symptom severity at
posttreatment. These results suggest that patients who can reduce their use, or initiate and
maintain abstinence during treatment, may experience lower levels of PTSD symptom
severity at the end of the treatment phase and into the posttreatment phase. However, it is
worth noting that this difference suggested that each additional day of use of the primary
substance of abuse was only associated with 1.50 higher points on the MPSS-SR (without
taking treatment type into account), a 1.3% difference on the scale of PTSD symptom
severity.

Author Manuscript

Did one treatment provide greater benefit for PTSD symptom severity when individuals
continued to use substances?
Our final model attempted to examine whether either COPE or RPT would be more
beneficial for patients with PTSD and SUD who continue to use their primary substance of
abuse during treatment. We did not find evidence of a three-way interaction between
treatment, continued use of substances, and the rate of change, suggesting that there were no
differences in how levels of continued substance use influenced the rate of change between
the two treatments. In addition, there was not a two-way interaction between treatment and
J Consult Clin Psychol. Author manuscript; available in PMC 2019 October 01.
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continued use of substances, indicating that the way continued substance use impacts
treatment outcomes, is not different between the two treatments. However, there were two
significant two-way interactions that indicated the following: (1) individuals in COPE
experienced a more rapid change in PTSD symptom severity, albeit a small effect; and (2)
those with greater continued substance use had a slower change in their PTSD symptom
severity, although it should be noted that the effect size was negligible therefore limiting
generalizability to clinical populations. For these exploratory findings, we examined mean
levels of PTSD symptom severity for those in COPE and RPT at various levels of substance
use to examine whether these two two-way interactions could approximate clinicallymeaningful differences in endpoints using the simple slopes for and examined significance
using the confidence intervals around each estimate. Overall, results highlight that under
certain conditions, treatment in general can reduce PTSD symptom severity to subthreshold
levels even with continued substance use. Importantly, there were two exceptions to this: (1)
individuals in COPE who were abstinent from their primary substance of abuse or used once
in the week prior to the end of the treatment phase achieved levels in the asymptomatic
range; and (2) individuals in RPT who used daily in the week prior to the end of treatment
remained in the threshold range. Only the estimates for individuals in COPE who were
abstinent and those in RPT who used daily were found to be significantly different from one
another. Overall, our findings provide, initial, key support for three main points: 1) both RPT
and COPE were associated with significant reductions in PTSD symptom severity for those
with PTSD and SUD; 2) exposure-based processing can be accomplished in patients with
SUD regardless of frequency of use during treatment, and 3) for those who use daily during
treatment, substance-use focused only treatment may not provide enough support to reduce
PTSD symptom severity. However, we emphasize that neither inferences nor conclusions
should be made based on these two small effects, particularly given the sample size of the
study. Instead, these should be taken as exploratory analyses that may guide hypotheses in
future studies with larger samples.
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Author Manuscript

Limitations

Author Manuscript

Several limitations should be noted. Like all controlled trials with PTSD and SUD (as noted
most recently by Roberts, Roberts, Jones, and Bisson, [2015]), attrition over the entire study
period may have reduced power. However, data analytic techniques (such as the ability to
include all 82 cases in the PTSD analysis and lose only 7 in the DSU analysis) may
outweigh this relative limitation. In addition, the degree of missingness at each week may
impact the power to detect the influence of either predictor at the intercept (which is
dependent on how time is centered in the model), depending on how much missingness
occurred at each week. For example, there was more power to detect the impact of treatment
assignment at session 1, than at the end of the treatment phase, where fewer participants
attended. This difference in power is accounted for in the width of the confidence interval
around the estimates. Nonetheless, due to power considerations, we underscore that the
findings we report should be considered preliminary and in need of replication. We utilized
retrospective self-report of PTSD and SUD symptoms, which are subject to biases in recall
and social desirability. We employed only DSU for the primary substance of abuse, which
may have limited our sensitivity in capturing relevant associations of other substances of
abuse with PTSD symptoms: for example, the potential for an increase in cannabis use to
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manage sleep or anxiety with a decrease in observed primary substance of abuse (alcohol or
cocaine). These changes in other drug use are potentially important to know in relation to
treatment type. Analysis of the quantity or severity of substance use may shed further light
on the relationship between PTSD symptoms and substance use. Because of our exclusion
criteria, findings may not be generalizable to individuals who are within 8 weeks of starting
psychotropic or substance abuse medication treatments. Finally, the lack of follow-up
assessments beyond three months limited our ability to examine the durability of changes
observed.
Conclusion and Future Directions

Author Manuscript

Taken as a whole, our growth curve analyses revealed important details bearing on the
process of psychotherapy change in two potent treatments for PTSD and SUD. The findings
provide more support for the use of RPT as a beneficial treatment for this comorbid group
(i.e., Hien, Cohen, Miele & Capstick, 2004; Ruglass et al., 2017). Analyses also provide
solid evidence that trauma processing exposure-based techniques can lead to significant
reductions in PTSD symptoms, even when individuals continue to use substances. Moreover,
our findings suggest that when individuals continue to use their primary substance of abuse
daily, a substance-use focused only treatment may not provide enough support to reduce
PTSD symptom severity. Future replication studies must examine these differences with
prospective tracking over longer periods of time, as well as examining cross-lagged impact
of PTSD changes on substance use outcomes over time. Contrary to concerns which have
traditionally led those conducting controlled trials of PE for PTSD to exclude active
substance users from their research, these findings provide further support that exposurebased techniques tailored for SUD can be conducted without jeopardizing PTSD or SUD
recovery.
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Public Health Significance Statement: Study findings provide important support for three
main points: 1) both RPT and COPE were associated with significant reductions in PTSD
symptom severity for those with PTSD and SUD; 2) exposure-based techniques can be
accomplished in patients with SUD regardless of frequency of use during treatment, and
3) for those who use daily during treatment, substance-use focused only treatment may
not provide enough support to reduce PTSD symptom severity.
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Figure 1.

CONSORT Diagram of participant flow through the protocol. PTSD = posttraumatic stress
disorder; DX = diagnosis; COPE = Concurrent Treatment of PTSD and SUD using
Prolonged Exposure; RPT = Relapse Prevention Therapy; AMCG = Active Monitoring
Control Group
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Figure 2.

Estimated mean levels of PTSD symptom severity for COPE and RPT at the point that is
infinitely close to posttreatment, at different levels of lagged DSU (i.e., DSU during the last
week of treatment). The bottom shaded region suggests asymptomatic levels of PTSD
symptom severity (about 17 points and lower) on the MPSS-SR, while the top shaded region
suggests mild/subthreshold levels of PTSD symptom severity (about 17.5 to 34.99 points)
(Ruglass et al., 2014). The asterisks indicate that those estimates are significantly different
from one another.
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Demographic, baseline clinical characteristics, and baseline and posttreatment outcomes
Characteristic

COPE
n = 39
n or M (% or SD)

RPT
n = 43
n or M (% or SD)

p-value

43.08 (10.00)

44.21 (9.05)

.590

11 (28.2%)

16 (37.2%)

.386

Demographic
Age
Female
Race/Ethnicity

.490

Black/African American

21 (53.8%)

28 (65.1%)

Hispanic/Latino

10 (25.6%)

9 (20.9%)

White

6 (15.4%)

6 (14.0%)

Other

2 (5.1%)

0

13.31 (1.92)

13.13 (2.46)

.714

32 (82.1%)

35 (81.4%)

.949

Alcohol Dependence

30 (76.9%)

35 (81.4%)

.618

Substance Dependence

25 (64.1%)

30 (69.8%)

.586

Alcohol and Substance Dependence

16 (41.0%)

24 (55.8%)

.181

19 (48.7%)

18 (41.9%)

Education (years)

Author Manuscript

Full PTSD
Alcohol and substance use

Primary substance

.519

Alcohol

Author Manuscript

Cannabis

3 (7.7%)

4 (9.3%)

Cocaine

6 (15.4%)

6 (14.0%)

Alcohol and stimulants

8 (20.5%)

13 (30.2%)

Other polysubstance

3 (7.7%)

2 (4.6%)

Major Depressive Disorder

13 (33.3%)

16 (37.2%)

.714

Baseline

54.26 (24.60)

57.49 (24.33)

.550

Posttreatment

36.11 (28.04)

26.64 (24.30)

.237

3-month Follow-Up

26.88 (23.39)

25.95 (25.60)

.898

Baseline DSU

4.21 (2.67)

4.05 (2.31)

.776

Baseline Abstinence (0 DSU)

6 (15.4%)

2 (4.76%)

.146

Posttreatment DSU

2.11 (2.68)

1.04 (1.71)

.114

Posttreatment Abstinence (0 DSU)

8 (44.4%)

12 (50%)

.764

PTSD Symptom Severity

Weekly Days of Substance Use (DSU)

3-month Follow-Up DSU

1.84 (2.30)

0.90 (1.52)

.116

3-month Follow-Up Abstinence (0 DSU)

10 (40.0%)

13 (65.0%)

.136

Author Manuscript

Note. Descriptive statistics for outcome variables at posttreatment and the three-month follow-up were based on the sample of participants that
attended the post-treatment and three-month follow-up assessments. At post-treatment, N = 43 (COPE = 18, RPT = 25). At the three-month followup, N = 46 (COPE = 25, RPT = 21).
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---

COPE

Lagged DSU

−0.27

Time-Posttreatment Phase

---

Lagged DSU x Time-Treatment Phase

Lagged DSU x Time-Treatment Phase x Treatment
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--

--

--

7404.85
7442.97

--

--

--

−0.52*

−0.23

−0.03 [−0.10,0.03]

--

−2.04***

--

−6.24

−1.31[−1.49,−1.12]

--

--

Ref

32.58***

25.07***

B

--

--

--

−.30 [−.54, −.05]

−0.03[−0.09,0.04]

5955.68
5992.05

--

0.10

--

--

−0.04

−2.24***

5951.80
5997.27

NS

0.14*
--

NS

0.05[−0.01,0.12]

−0.79**

0.05

−2.00***

--

--

0.00[−0.09,0.08]

−1.26[−1.54,−0.97]

1.85**

1.50*

−1.17[−1.39,−0.95]

−7.81

--

Ref

25.77***

22.95***

B

−0.26[−0.67,0.16]

0.84[0.12,1.56]

d [95%CI]

--

.08 [.01, .15]

−.44 [−.75, −.13]

--

--

1.04 [.30, 1.77]

0.31[0.23,−0.13]

--

--

d [95%CI]

Final Model with Treatment
and Lagged DSU
+
N = 75

--

23.42***

20.36***

B

Model with Lagged DSU
+
N = 75

--

--

--

d [95%CI]

Model with Treatment
N = 82

p < .05.

*

Note. DSU = Days of Substance Use. The intercept represents the expected value of PTSD symptom severity when all other predictors are held constant at 0, while the slope represents the expected
difference in PTSD symptom severity given a one-unit change in time (all other variables held constant). All predictors are interpreted similarly to the slope and represent the expected difference due to a
one-unit change in the predictor (all other predictors held constant). Treatment was coded dichotomously with RPT equal to 0. Lagged days of use ranged from 0 to 7 and represented the reported days of
use for the previous assessment (e.g., at session 1, lagged days of use = days of use at the MI session).

AIC
BIC

7406.76
7435.35

--

Lagged DSU x Treatment

Fit Statistics

--

Treatment x Time-Treatment Phase

Interactions

−2.28***

Time-Treatment Phase

Rate of Change:

--

RPT

--

--

29.98***

Intercept-Posttreatment

Treatment

--

22.24***

d [95%CI]

Intercept-Session 12

Initial Status:

B

Linear Growth Model
N = 82

Regression coefficients, effect sizes and confidence intervals for piecewise models examining trajectories of PTSD symptom severity
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Seven participants were excluded from this model because they had insufficient data on the DSU variable.

+

p < .001.

p < .01.
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